Search Within

Colleen Dorsey

Formats
  1. Meeting Abstract (11)
  2. Journal Article (5)
Groups
  1. Department of Medicine (15)
  2. Hematologic Malignancies, Division of (15)
  3. Adult Leukemia (14)
  4. Center for Hematologic Malignancies (14)
  5. Lymphoma (8)
  6. Nursing (7)

More Groups

People
  1. Anthony Mato (14)
  2. Lindsey Roeker (13)
  3. Andrew Zelenetz (8)
  4. Julie Goodfriend (5)
  5. Katherine Whitaker (3)
  6. Lisa Sarmasti (3)

More People

Years
  1. 2022 (2)
  2. 2021 (1)
  3. 2020 (4)
  4. 2019 (7)
  5. 2018 (2)
Publications
  1. Blood (4)
  2. Clinical Cancer Research (3)
  3. Hematological Oncology (3)
  4. Leukemia and Lymphoma (3)
  5. Blood Advances (1)
  6. Journal of Clinical Oncology (1)

More Publications

Publishers
  1. American Society of Hematology (5)
  2. American Association for Cancer Research (3)
  3. Taylor & Francis Group (3)
  4. Wiley Blackwell (3)
  5. American Society of Clinical Oncology (1)
  6. Oncology Nursing Society (ONS) (1)

Results (16)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Adding umbralisib and ublituximab (U2) to ibrutinib in patients with CLL: A phase II study of an MRD-driven approach
    Journal Article

    Roeker, L. E.; Feldman, T. A.; Soumerai, J. D.; Falco, V.; Panton, G.; Dorsey, C.; Zelenetz, A. D.; Falchi, L.; Park, J. H.; Straus, D. J.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • A phase 2 study evaluating the addition of ublituximab and umbralisib (U2) to ibrutinib in patients with chronic lymphocytic leukemia (CLL): A minimal residual disease (MRD)-driven, time-limited approach
    Meeting Abstract

    Dorsey, C.; Falco, V.; Pena-Velasquez, C.; Lebowitz, S.; Purdom, M.; Panton, G.
    Oncology Nursing Forum (2022)

    Fulltext@MSK | Save
  • Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy
    Journal Article

    Mato, A. R.; Ghosh, N.; Schuster, S. J.; Lamanna, N.; Pagel, J. M.; Flinn, I. W.; Barrientos, J. C.; Rai, K. R.; Reeves, J. A.; Cheson, B. D.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Assessment of the efficacy of therapies following venetoclax discontinuation in CLL reveals BTK inhibition as an effective strategy
    Journal Article

    Mato, A. R.; Roeker, L. E.; Jacobs, R.; Hill, B. T.; Lamanna, N.; Brander, D.; Shadman, M.; Ujjani, C. S.; Yazdy, M. S.; Perini, G. F.; more...
    Clinical Cancer Research (2020)

    Fulltext@MSK | Save
  • Comparative analysis of targeted therapies in relapsed/refractory chronic lymphocytic leukemia (R/R CLL)
    Meeting Abstract

    Mato, A.; Roeker, L.; Eyre, T.; Ujjani, C.; Lamanna, N.; Hill, B.; Barr, P.; Lansigan, E.; Cheson, B. D.; Yazdy, M.; more...
    Leukemia and Lymphoma (2020)

    Fulltext@MSK | Save
  • Hypertension in ibrutinib-treated patients with chronic lymphocytic leukemia (CLL)
    Meeting Abstract

    Roeker, L.; Yazdy, M.; Gashonia, L.; Narkhede, M.; Goodfriend, J.; Rhodes, J.; Kennard, K.; Dorsey, C.; Sarmasti, L.; Calivo, K.; more...
    Leukemia and Lymphoma (2020)

    Fulltext@MSK | Save
  • Phase I/II triple therapy study of umbralisib and ublituximab ("U2") combined with checkpoint inhibition in patients with rel/ref CLL and Richter's transformation
    Meeting Abstract

    Mato, A.; Svoboda, J.; Luning-Prak, E.; Schuster, S.; Tsao, P.; Dorsey, C.; Sarmasti, L.; Becker, P.; Brander, D.; Geyer, M.; more...
    Leukemia and Lymphoma (2020)

    Fulltext@MSK | Save
  • Veneto-STOP study: Sequential assessment of minimal residual disease by next generation sequencing to optimize outcomes and minimize exposure in venetoclax-treated CLL patients
    Meeting Abstract

    Ujjani, C. S.; Roeker, L. E.; Shadman, M.; Whitaker, K. J.; Jacob, A. P.; Geyer, M. B.; Dorsey, C.; Zelenetz, A. D.; Mato, A. R.
    Blood (2019)

    Fulltext@MSK | Save
  • Efficacy of therapies following venetoclax discontinuation in CLL: Focus on B-cell receptor signal transduction inhibitors and cellular therapies
    Meeting Abstract

    Mato, A. R.; Roeker, L. E.; Eyre, T. A.; Jacobs, R.; Hill, B. T.; Lamanna, N.; Brander, D. M.; Shadman, M.; Ujjani, C.; Yazdy, M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Tumor lysis, adverse events, and dose adjustments in 297 venetoclax-treated CLL patients in routine clinical practice
    Journal Article

    Roeker, L. E.; Fox, C. P.; Eyre, T. A.; Brander, D. M.; Allan, J. N.; Schuster, S. J.; Nabhan, C.; Hill, B. T.; Shah, N. N.; Lansigan, F.; more...
    Clinical Cancer Research (2019)

    Fulltext@MSK | Save